• Why are PROs 'ultimately' to be reported and not at start up? • What is the aim of this project please? • "The pilot phase incorporating only ovarian, tubal and peritoneal cancers was conducted to assess the feasibility of the registry methodology and assess the support of a quality initiative of this nature amongst clinicians and other key stakeholders." Has this already been done?? Strengths and limitations:
• "This is a clinician-driven initiative, using a model for data collection that should reduce long-term costs associated with registry operations." I am not sure how this is/will be achieved and this is not explained anywhere else? Introduction:
• "A population-based study of 1192 women diagnosed with ovarian cancer in 2005 showed that compared with women from relatively socioeconomically advantaged areas, women from relatively disadvantaged areas had a 21% higher risk of dying during follow-up." How does this follow the previous sentence regarding variation in treatment? Is there evidence for such variation in treatment across the continent? This is detailed later, but needs to link up here.
• "The National Gynae-Oncology Registry (NGOR) is a new multimodular CQR which aims to record diagnostic, treatment and outcome data of patients with newly diagnosed gynaecological cancers, and to use this information to monitor and minimise variation in care, improve patient outcomes, and identify trends and potential gaps in service provision." Is the registry in place and running? This is not clear to me.
• "Key causes of variation in patient outcomes": this has been discussed earlier in the introduction. See previous comment. Methods: • This is a non-interventional study collecting primarily secondary use data from pre-existing clinical datasets." What is the aim of the project though? Where are the objectives? Is it a pilot of the registry or a new module of the registry -this is unclear throughout?? • What are the pre-existing datasets -how do they link with this registry?
• "This novel method is expected to allow for high-quality, consistent data collection in a more time and cost-effective method, avoiding duplication of effort." If this is the transfer of retrospective data from one dataset to another -how does this make the data high quality?
• "across the private vs. public sector" -could the authors kindly explain if the methodology is the same throughout? • "The registry Steering Committee aims to eventually include >90% of patients diagnosed with gynaecological cancers": how will this be achieved? • "In the future, if sites without databases wish to contribute to the registry, the methodology will need to be adapted…". Will this not bias the data in the registry? How will this be avoided? How many services do not have a database and why do they not?
• "Alternatively, sites may choose to enter data directly into the registry. In this instance, limited access to the registry's electronic database will be granted allowing specific site personnel access to only that site's records.:" This contradicts the earlier described methodology and how will funding be achieved for this -the reason given for the secondary transfer of data??
• "Data will be risk-adjusted using additional data items such as comorbidity data, participant age, body mass index and stage at diagnosis, to ensure that fair comparisons between institutions and clinicians can be made." Please could the authors provide more detail on this.
REVIEWER
Gregg Nelson Tom Baker Cancer Centre, Canada REVIEW RETURNED 25-Nov-2019 GENERAL COMMENTS I applaud the authors on a well-written paper describing a protocol for the development of an Australian multi-module clinical quality registry for gyn cancers. I would like the authors to address the following question: -It is highlighted a number of times that there is variation in outcome and access to care for indigenous and lower SES patients; how will this registry overcome the barriers of ensuring that the outcomes in these patients are adequately captured? Too often in remote/low resourced centers there is an inability/challenge to participate in these types of registries.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1 (R1), Comment 1 (C1). The introduction is very long and repetitious, with no clear aim. It would be helpful if there were an introductory paragraph with the aim and then background in an ordered manner and shortened text. I was still unclear what the aim of the paper at the conclusion -is it to pilot the registry *which seems to be running) or a new module? The authors should kindly make clear at the beginning and in the abstract exactly what this protocol describes. If it the setting up of a new module of the existing database, please could the authors be clear what has already been done and what this is a protocol for. The background is important, but it is repetitive and the reader is not sure where it is heading in terms of the protocol?
Response: The authors acknowledge and thank the reviewer for this feedback. We have edited the abstract and restructured the introduction to make the paper clearer. Please see 'method & analysis' section of the abstract on page 2 of the amended manuscript.
Amended text: The National Gynae-Oncology Registry (NGOR) aims to capture clinical data on all newly diagnosed cancers of the uterus, ovary, fallopian tubes, peritoneum, cervix, vulva and vagina in Australia with a view to using these data to support improved clinical care and increased adherence to 'best practice'. Data are sourced from existing clinical databases maintained by clinicians and/or hospital gynaecological cancer units. The registry was developed by a group of likeminded clinicians, primarily gynaecologic oncologists, in collaboration with the Cancer Research Program at Monash University. The pilot phase incorporating only ovarian, tubal and peritoneal cancers has recently been conducted to assess the feasibility of the registry methodology and assess the support of a quality initiative of this nature amongst clinicians and other key stakeholders.
Response cont'd. See also page 4 -the third paragraph in the introduction has been moved to the start of the paper, and the remaining paragraphs of the introduction now sit under the heading 'Background'. We acknowledge the comments around length of the background, however we have respectfully retained the majority of said information as we believe it is of relevance in justifying why a registry of this nature is required in Australia.
R1, C2. … data lacking in key areas: there is an issue with not collecting data from services without an existing database and biasing the results?
Response: The authors acknowledge and thank the reviewer for this feedback. We have added a section titled 'The Future' to the end of the Methods section (see page 10, paragraph 3).
New text: The Future… The establishment of the NGOR allows Australia to quantify variation and improve outcomes for patients with gynaecological cancers, and facilitate adherence to best practice care nationally. Over time, as a greater proportion of the population-of-interest are recruited to the registry, the registry should increase its potential to identify variation across high versus low volume sites, remote versus regional sites and draw other comparisons. In recruiting high volume sites first, solid evidence of 'best practice' and what is achievable realistically with the greatest resources and specialist involvement, the registry should provide a solid framework against which future lower volume and less established sites can be compared against both in performance against QIs as well as fundamental aspects of clinical management that may be amenable. By providing indisputable evidence of the impact of known barriers to best practice care for remote and low volume centres, the registry aims to improve care nationwide.
Response cont'd. We have also included additional text in paragraph 5 of the subsection 'Trialling a Different Method for Capturing Data' in an effort to explain this limitation and plans to address it. Please refer to amended manuscript page 10 paragraph 1.
Amended text: This is a non-interventional study primarily using previously collected clinical data from pre-existing clinical databases maintained by consulting gynaecologic oncologists and gynaecologic oncology units in major public hospitals across Australia. The registry pilot aimed to demonstrate the feasibility and ease of this predictably more cost-effective and sustainable method of registry operations given the considerable costs associated with manual data collection through medical record review by central, trained data collectors who are required to interpret clinical notes written for a different purpose. This novel method is expected to allow for high-quality, consistent data collection in a more time and cost-effective method, avoiding duplication of effort.
R1, C3. There are few details about data confidentiality and anonymity?
Response: The authors respectfully disagree. Please refer to subsection 'Data Cleaning, Analysis and Reporting' of the Methods section: "Data will then be aggregated and reported against the predetermined QIs. No identifying or potentially re-identifiable data will be published. Participating sites and clinicians will receive regular benchmarked reports once the CQR has reached maturity, illustrating how their performance in respect to each QI compares with their de-identified counterparts." R1, C4. There is little detail about how or whether services get to see their data before publication.
Response: The authors thank the reviewers for this comment and acknowledge the lack of clarity around this issue in the current draft. We have added an extra sentence to the final paragraph of the 'Data Cleaning, Analysis and Reporting' subsection of the Methods, elaborating on how data are dealt with prior to any report or publication. See page 10, paragraph 1.
New text: Sites identified as performing poorly against a QI will be provided ample opportunity to review their data, and the registry data and methodology will be audited to ensure that any publiclyreported QI performance is a true reflection of care provision and not that of data collection error or misinterpretation of data. Furthermore, the registry Steering Committee will be required to approve requests for data access in the event that researchers, internal or otherwise, wish to access NGOR data for additional research and publication.
R1, C5. There is little patient engagement in the methods?
Response: The authors apologise however we are unsure what this comment means. Yes, the registry has little patient engagement purely due to the nature of a clinical quality registry relating to care provision. The clinicians and those involved in providing care have been integral to the process, and these are the persons who have guided the quality indicator development. New text: The NGOR Steering Committee intends to incorporate the collection of Patient Reported Outcomes (PROs) in the future, to compliment the clinical data on quality of care. PROs will provide additional information that can only be obtained from patients about quality of care, and is invaluable to a clinical quality registry such as this. Patient Reported Outcome Measures (PROMs) are not currently used in the registry as the best and more appropriate tool, as well as the method with which they will be incorporated to the registry, and how the data will be used must be determined in a substudy. This is planned for the near future, but could not be performed before the clinical data requirements were finalised. R1, C7. What is the aim of this project please?
Response. Please see response to R1, C1.
R1, C8. The pilot phase incorporating only ovarian, tubal and peritoneal cancers was conducted to assess the feasibility of the registry methodology and assess the support of a quality initiative of this nature amongst clinicians and other key stakeholders." Has this already been done??
Response. Yes, the ovarian cancer module has already been piloted alongside the registry infrastructure and methodology. The authors acknowledge this lack of clarity and have amended the manuscript to make the timing of the paper in relation to the study clearer. Please see the amended manuscript page 4, paragraph 1 'Introduction', last line "The key reason for piloting…".
New text: The key reason for piloting one, rather than all modules, was to allow the registry infrastructure to be developed and piloted on a smaller scale. Once the registry has matured, additional modules can be piloted using -what will then be -an established infrastructure.
Response cont'd. See also amended text in the introduction of the abstract on page 2.
New text: The registry infrastructure has been developed in conjunction alongside the inaugural ovarian, tubal and peritoneal (OTP) module, allowing for concurrent piloting of the methodology and one module. Additional tumour modules will be developed in time to cover the other gynaecological tumour types.
Response cont'd. Given the confusion regarding the current status of the registry the authors have added the following text in the introduction to clarify.
New text: The NGOR is currently in a transitional phase, working to develop these additional modules and adjusting the ovarian, tubal and peritoneal (OTP) module.
Response cont'd. See also amended text in "The Future" section on page 10.
New text: The registry is currently in a transition phase, with funding secured for additional modules to be developed and run within the piloted framework, alongside the continuing ovarian, tubal and peritoneal module.
R1, C9. (Strengths and limitations) "This is a clinician-driven initiative, using a model for data collection that should reduce long-term costs associated with registry operations." I am not sure how this is/will be achieved and this is not explained anywhere else?
Response: The authors acknowledge this comment and thank the reviewer for identifying this. We have added 'through the use of previously collected clinical data' to the end of this sentence (in article summary, 'strengths and limitations of this study' -see amended manuscript page 2, final paragraph.
Amended text: This is a clinician-driven initiative, using a model for data collection that should reduce long-term costs associated with registry operations through the use of previously collected clinical data.
Response cont'd. In addition, we would like to highlight that this has been addressed in Methods subsection "Trialling a Different Method for Capturing Data': "given the considerable costs associated with manual data collection through medical record review by central, trained data collectors. This novel method is expected to allow for high-quality, consistent data collection in a more time and costeffective method, avoiding duplication of effort." R1, C10. (Introduction) "A population-based study of 1192 women diagnosed with ovarian cancer in 2005 showed that compared with women from relatively socioeconomically advantaged areas, women from relatively disadvantaged areas had a 21% higher risk of dying during follow-up." How does this follow the previous sentence regarding variation in treatment? Is there evidence for such variation in treatment across the continent? This is detailed later, but needs to link up here.
Response: This statement seeks to further describe variation in patient outcomes, which does not exist purely because of variation in treatment. The registry seeks to and has the potential to identify variation in practice caused by any and all factors, including important social determinants associated with treatment provision limitations known to affect SEIFA disadvantaged and rural areas.
R1, C11. "The National Gynae-Oncology Registry (NGOR) is a new multi-modular CQR which aims to record diagnostic, treatment and outcome data of patients with newly diagnosed gynaecological cancers, and to use this information to monitor and minimise variation in care, improve patient outcomes, and identify trends and potential gaps in service provision." Is the registry in place and running? This is not clear to me.
Response: addressed in response to a previous comment (R1, C8).
R1, C12
. "Key causes of variation in patient outcomes": this has been discussed earlier in the introduction. See previous comment.
Response: addressed in response to a previous comment. R1, C20. (Methods) "Data will be risk-adjusted using additional data items such as comorbidity data, participant age, body mass index and stage at diagnosis, to ensure that fair comparisons between institutions and clinicians can be made." Please could the authors provide more detail on this.
Response: The authors respectfully believe this has been explained on page 9 in subsection 'Data Cleaning, Analysis and Reporting'.
Reviewer 2, Comment 1. It is highlighted a number of times that there is variation in outcome and access to care for indigenous and lower SES patients; how will this registry overcome the barriers of ensuring that the outcomes in these patients are adequately captured? Too often in remote/low resourced centers there is an inability/challenge to participate in these types of registries.
Response: The authors agree and thank the reviewer for pointing out the lack of clarity around this issue. We have amended the manuscript accordingly. Please see amended manuscript page 9, paragraph 5 and the new Methods sub-section titled 'The Future' on page 10 immediately preceding the conclusion (already covered in a previous response).
New text: Together these account for the majority of public gynaecologic oncology treatment centres in the participating States. Although commencing with the recruitment of these specialist centres may introduce bias to the dataset and not accurately represent the Australian population being treated for these cancers, it has been deemed as the most cost-effective and feasible methodology and will not limit the growth of the registry over time. Other smaller centres without major gynaecologic oncology units, as well as the units in other as-of-yet not participating States will be recruited once registry methodology and each module's QI set has been assessed for usefulness and feasibility of collection. The registry will gradually work towards the ultimate target of total population capture, or as close to this as possible.
